China News Service, Beijing, April 30 (Reporter Zhang Su) "Traditional coronary angiography has limitations, it is easy to misjudge the degree of stenosis, and it is difficult to accurately determine whether a patient needs to install a stent." Zhu Rui, founder of Weiguang Medical, on the 30th The reporter said that optical coherence tomography (OCT), with its high resolution, has better ability to recognize tissue features.
After review by the State Drug Administration, the innovative product "cardiovascular optical coherence tomography equipment and accessories" produced by Shenzhen Zhongke Microlight Medical Device Technology Co., Ltd. was approved for listing. Zhu Rui explained that using OCT technology, the image is easier to interpret, and can effectively identify thin fiber cap plaque (TCFA), vulnerable plaque, thrombus and in-stent restenosis, which can guide the doctor to give a more scientific and effective treatment plan.
He said that the next step will be to fully promote the large-scale production of products, and continue to promote the innovation and popularization of interventional imaging tools to provide doctors with accurate and easy-to-use interventional diagnosis and treatment integrated equipment.
According to reports, OCT as the highest resolution intraluminal imaging technology, makes up for the shortcomings of traditional imaging technology. Chen Yundai, a well-known Chinese cardiovascular expert, noted that the 2013 European Society of Cardiology (ESC) guidelines for stabilizing angina listed OCT as a category IIB recommendation, and the 2018 ESC / EACTS guidelines raised the OCT recommendation to IIA.
The low-light medical team born out of the Chinese Academy of Sciences was established in 2012 and completed the engineering prototype development in 2015. In June 2016, they conducted the first animal cardiovascular stent implantation experiment and used the OCT system to observe the adherence of the stent after implantation. In this process, the low-light medical team has conducted rigorous clinical trials in conjunction with the Chinese People's Liberation Army General Hospital, Beijing Anzhen Hospital affiliated to Capital Medical University, and Zhongshan Hospital affiliated to Fudan University.
Zhu Rui revealed that as of April 30, the Shiguang Medical Team has deployed a total of 71 effective patents, including 29 inventions and 8 authorized inventions.
In fact, although China is already the second largest medical market in the world, large-scale highly sophisticated diagnostic instruments such as CT, magnetic resonance imaging (MRI), nuclear medicine, and cardiovascular imaging have long been recognized by the "GPS" three giants. Monopoly, namely: General Electric GE of the United States, Philips of the Netherlands, Siemens of Germany. In recent years, with the advancement of national medical technology and the maturity of the supporting industrial chain, the "domestic substitution import" in the field of medical devices has been increasing year by year.
Zhu Rui believes that as a relatively high-tech segment in the industry, allowing OCT equipment to be made in China will greatly promote the precise treatment of cardiovascular diseases in China. He also said that as a "hard technology" team that has been committed to the innovation of imaging equipment for cardiovascular interventional surgery, they have achieved breakthroughs in many aspects such as technical independence, reliable equipment and price.
Zhu Rui and his colleagues are also fulfilling the mission of transforming national scientific and technological achievements, with particular emphasis on industry-university-research cooperation and in-depth integration with market demands. They have established cooperation with well-known medical science and technology institutions at home and abroad, such as the Chinese Academy of Sciences, the Chinese Academy of Cardiology Doctor Innovation Club (CCI) Innovation School, Harvard Medical School, the Netherlands Erasmus Medical Center, Massachusetts General Hospital, etc., to automatically detect vulnerable plaques. , Intravascular pulsed laser volume reduction, dual-modal integrated microcatheter, and other fields have made innovative breakthroughs.
It is worth mentioning that Weguang Medical has successively completed multiple rounds of financing of more than 100 million yuan including Zhongke Chuangxing, Qidi Venture Capital, and West High Investment. "We have been growing up with Weiguang Medical for a long time. We are very optimistic about the team's technical strength and entrepreneurial pursuit, and we will continue to pay attention to the market value of the OCT industry." Mi Lei, founding partner of Zhongke Chuangxing. (Finish)